Brain structural changes in schizoaffective disorder compared to schizophrenia and bipolar disorder

Amann, Benedikt L.; Canales‐Rodríguez, Erick J.; Madre, Mercè; Raduà, Joaquim; Monté, Gemma C.; Alonso‐Lana, Silvia; Landín-Romero, Ramón; Moreno‐Alcázar, Ana; Bonnín, C.M.; Sarró, Salvador; Ortíz-Gil, Jordi; Gomar, Jesús J.; Moro, Noemí; Fernández-Corcuera, Paloma; Goikolea, José Manuel; Blanch, Jordi; Salvador, Raymond; Vieta, Eduard; McKenna, Peter; Pomarol‐Clotet, Edith

doi:10.1111/acps.12440

Cited by 65 publications

(58 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[9][10][11][12] Similarities between the cognitive profiles of these disorders are consistent with a shared under lying neurobiology that differs quantitatively rather than qualitatively across the diagnostic groups. 1,7,8 Indeed, previ ous studies have indicated overlap in regions of greymatter reduction (although less consistently in bipolar disorder) [35][36][37][38] and genetic susceptibility. [39][40][41][42] While neurocognitive impairments were evident across all diagnoses, impairments in social cognition were not present in bipolar disorder but were observed in schizophrenia and schizoaffective disorder.…”

Section: Discussionmentioning

confidence: 99%

Examining cognition across the bipolar/schizophrenia diagnostic spectrum

Lynham

Hubbard

Tansey

et al. 2018

jpn

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Examining cognition across the bipolar/schizophrenia diagnostic spectrum

Lynham

Hubbard

Tansey

et al. 2018

jpn

View full text Add to dashboard Cite

“…Three studies found in SCZ patients GM reductions at the level of cerebellum (Molina et al 2011;Ivleva et al 2013;Amann et al 2016) Given the key function of these structures in learning, memory, attention and information transmission, the GM deficits of these structures in SCZ patients seem to be consistent with the relevant cognitive impairment associated with SCZ (Andreasen et al 1994;Brambilla et al 2013).…”

mentioning

confidence: 96%

“…In these studies, SCZ and BD were compared between each other and to HC, as well as to schizoaffective disorder (SAD) patients in Ivleva et al (2012Ivleva et al ( , 2013; Amann et al (2016), and to their firstdegree relatives in Ivleva et al (2013). It is worth noticing that Yüksel et al (2012) included SAD patients in the SCZ group.…”

mentioning

confidence: 99%

“…It is worth noticing that Yüksel et al (2012) included SAD patients in the SCZ group. Although the clinical characteristics of patients varied from study to study, the large majority considered chronic patients (except from Farrow et al 2005) and BD patients with lifetime psychosis (except from Molina et al 2011;Amann et al 2016). The differences in clinical symptoms and pharmacological therapies between studies represent a confounding factor that should be taken into account when interpreting their findings.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Neuroanatomical voxel-based profile of schizophrenia and bipolar disorder

Maggioni

Altamura

Brambilla

2016

Epidemiol Psychiatr Sci

View full text Add to dashboard Cite

This Section of Epidemiology and Psychiatric Sciences appears in each issue of the Journal to stress the relevance of epidemiology for behavioral neurosciences, reporting the results of studies that explore the use of an epidemiological approach to provide a better understanding of the neural basis of major psychiatric disorders and, in turn, the utilisation of the behavioural neurosciences for promoting innovative epidemiological research.The ultimate aim is to help the translation of most relevant research findings into every-day clinical practice. These contributions are written in house by the journal's editorial team or commissioned by the Section Editor (no more than 1000 words, short unstructured abstract, 4 key-words, one Table or Although schizophrenia (SCZ) and bipolar disorder (BD) share elements of pathology (Ellison-Wright and Bullmore, 2009), the neural mechanisms underlying these disorders are still under investigation. Up until now, many neuroimaging studies investigated the brain structural differences of SCZ and BD compared with healthy controls (HC), trying to identify the possible neuroanatomical markers for the two disorders. However, just a few studies focused on the brain structural changes between the two diagnoses. The present review summarises the findings of the voxel-based grey matter (GM) comparisons between SCZ and BD, with the objective to highlight the possible consistent anatomical differences between the two disorders. While the comparisons between patients and HC highlighted overlapping areas of GM reduction in insula and anterior cingulate cortex, the SCZ-BD comparisons suggest the presence of more generalised GM deficits in SCZ compared with BD. Indeed, in a number of studies, SCZ patients showed lower GM volumes than BD patients in fronto-temporal cortex, thalamus, hippocampus and amygdala. Conversely, only a couple of studies reported GM deficits in BD compared with SCZ, both at the level of cerebellum. In summary, the two disorders exhibit both common and specific neuroanatomical characteristics, whose knowledge is mandatory to develop innovative diagnostic and treatment strategies. (Email: marcella.bellani@univr.it; paolo.brambilla1@unimi.it)Epidemiology and Psychiatric Sciences (2016), 25, 312-316.

show abstract

“…[2,3] Until now, researchers have not decided on the independence of this disorder, and SAD is often included in the spectrum of schizophrenic disorders; rarely, it is referred to as bipolar disorder. [3][4][5][6][7] According to some studies, an overlap between schizophrenia, SAD and bipolar affective disorder type I was observed at the evaluation of genetic and biological parameters. [1,8,9] However, there are a number of modern clinical, molecular-genetic, biochemical and histological studies confirming the validity of segregation of such a nosological unit as schizoaffective disorder.…”

Section: Introductionmentioning

confidence: 99%

Combined Antirelapse Therapy in Patients with Schizoaffective Disorder: A Prospective Cohort Study

Nekrasov¹,

Khritinin²,

Сумарокова³

et al. 2016

Int J Biomed

View full text Add to dashboard Cite

Background: In most studies, patients with schizoaffective disorder (SAD) are often combined into one group along with schizophrenia patients or less commonly with those suffering from affective disorders, which makes it difficult to obtain data about the peculiarities of SAD treatment. Articles dedicated to SAD treatment in the interictal period are rare. Methods and Results:The prospective cohort study was conducted from 2011 to 2015. The study involved 86 patients diagnosed with SAD according to ICD-10. Patients received neuroleptics (NLs) as antirelapse therapy for 2 years (NL therapy); then mood stabilizers (MSs) were added to the antirelapse treatment (NL+MS therapy). The results of this combined therapy with MSs were evaluated after 2 years of treatment. Our results suggest that the use of combination therapy that includes antipsychotics and MSs leads to maintenance of a higher quality remission. Remission becomes more prolonged and affective swings less pronounced, resulting in improved quality of life in SAD patients. Improving the quality of remission can be attributed to the following characteristics of the combined therapy: a) the use of lower doses of neuroleptics; b) a reduction in the frequency and severity of mood swings; and c) an increase in patient compliance.Conclusion: The use of combined pharmacotherapy including antipsychotics and MSs produces a longer, high-quality remission. The inclusion of MSs in the scheme of treatment increases the patient adherence to a medication regimen. The use of MSs in combination therapy reduces affective fluctuations, thereby increasing the probability of maintaining remission with complete symptom relief. (Int J Biomed. 2016;6(2):119-123.).

show abstract

Brain structural changes in schizoaffective disorder compared to schizophrenia and bipolar disorder

Cited by 65 publications

References 51 publications

Examining cognition across the bipolar/schizophrenia diagnostic spectrum

Examining cognition across the bipolar/schizophrenia diagnostic spectrum

Neuroanatomical voxel-based profile of schizophrenia and bipolar disorder

Combined Antirelapse Therapy in Patients with Schizoaffective Disorder: A Prospective Cohort Study

Contact Info

Product

Resources

About